Author

T. Peacock

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:host-pathogen & immune response· 3 Approach:experimental assay· 2 Organism:human· 2 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1 Approach:genetic perturbation / CRISPR· 1 Research Focus:protein folding & dynamics· 1

Frequent Co-Authors

A. Abdullahi· 1 shared A. Chandran· 1 shared A. J. Mentzer· 1 shared A. Mavousian· 1 shared A. Mayer· 1 shared A. McKnight· 1 shared A. Otter· 1 shared A. Satwik· 1 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMicrobiology

A. Abdullahi

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

GGCX promotes Eurasian avian-like H1N1 swine influenza virus adaption to interspecies receptor binding

J. Zou, M. Jiang, R. Xiao, H. Sun, H. Liu, T. Peacock, S. Tu, T. Chen, J. Guo, Y. Zhao, W. Barclay, S. Xie, H. Zhou

This study identifies GGCX as a key factor enabling EA H1N1 SIV adaptation to human-type -2,6 sialic acid receptors through HA carboxylation, suggesting it as a potential antiviral target.

bioRxiv · Mar 18, 2024Microbiology

Large clones of pre-existing T cells drive early immunity against SARS-COV-2 and LCMV infection.

M. Milighetti, Y. Peng, C. C. S. Tan, M. Mark, G. Nageswaran, S. Byrne, T. Ronel, T. Peacock, A. Mayer, A. Chandran, J. Rosenheim, M. Wheelan, X. Yao, G. Liu, S. L. Felce, , B. Chain

The paper identifies high frequency naive T cell precursors that drive rapid T cell responses during early SARS-COV-2 and LCMV infections.

bioRxiv · Nov 8, 2022Immunology

SARS-CoV-2 B.1.617.2 Delta variant replication, sensitivity to neutralising antibodies and vaccine breakthrough

P. Mlcochova, S. A. Kemp, M. Shanker Dhar, G. Papa, B. Meng, S. Mishra, C. Whittaker, T. Mellan, I. Ferreira, R. Datir, D. Collier, S. Singh, R. Pandey, K. Ponnusamy, V. S. Radhakrishnan, , Saliba

This study evaluates the replication, antibody sensitivity, and vaccine efficacy of the SARS-CoV-2 B.1.617.2 Delta variant compared to other variants and vaccine-elicited immunity.

bioRxiv · May 8, 2021 · PreprintMicrobiology